Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.OCGN · Entity 5550 | Chief Medical Officer | January 02, 2025 | January 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2035-01-02 | Direct | 1,145,468 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 1,145,468 · Balance 1,145,468 F1: The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 6, 2025 17:01 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 1,145,468 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001062993-25-000404 · form4.xml · derivative · entry 1 Qamar Huma · CIK 0002015296 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,145,468 Underlying: Common Stock · 1,145,468 shares Expires 2035-01-02 F1 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 2, 2026, subject to continued service with the Issuer on the applicable vesting dates. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 17:41 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 308,465 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001062993-24-008488 · form4.xml · derivative · entry 1 Qamar Huma · CIK 0002015296 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,465 Underlying: Common Stock · 308,465 shares Expires 2034-04-16 F1 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on April 16, 2025, subject to continued service with the Issuer on the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.